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ABSTRACT 
Aims: To estimate the impact at two and three years post-surgery of implant-assisted 
latissimus dorsi (LDI) and autologous LD (ALD) flap breast reconstructions (BRRs) on patient-
reported outcomes (PROs), and secondarily, to determine whether baseline characteristics 
predict PROs.  
Methods: Multi-centre prospective cohort study. The European Organisation for Research and 
Treatment of Cancer Quality of Life Core Questionnaire (QLQ-C30) and breast cancer module 
(QLQ-BR23); Functional Assessment of Cancer Therapy-Breast and Hospital Anxiety and 
Depression Scale PROs, were completed pre-operatively and at 2- and 3-years after BRR. The 
effects of LDI and ALD, adjusted for baseline clinico-demographic characteristics, were 
estimated with multiple linear regressions. Effect-sizes over 0.5 were considered clinically 
important. 
Results: 206 patients (93 LDI and 113 ALD) were recruited (2007-2013); 66% were node 
negative; 34% received radiotherapy (RT). Women with adverse clinico-pathology were more 
likely to have received RT and undergo ALD. Each surgical group showed clinically important 
impacts at two and three-years, including improvements in emotional scales, but worse 
physical functioning, social well-being, body image and anxiety. RT adversely affected social 
function at two years (P=0.002). Women undergoing ALD BRR had significantly improved 
sexual functioning (P=0.003) at 3-years relative to those who had LDI BRR, even after adjusting 
for case-mix (P=0.0067). Younger women experienced worse arm symptoms (P=0.005) and 
physical well-being (P=0.006) than older women at 3-years. 
Conclusion: Clinically important changes occurred in physical functioning, breast symptoms, 
body image and psychological distress. These results will guide selection of key PRO domains 
and sample size calculations of future studies.   
Page 3 of 31
http://mc.manuscriptcentral.com/bjs
BJS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
FOR REVIEW ONLY
 4 
INTRODUCTION 
Improvements in early detection and systemic treatments of breast cancer have resulted in 
500,000 long-term survivors in the United Kingdom
(1)
. Currently, 53% of women are 
recommended for mastectomy with an increasing annual trend
(2)
. In 2009, 15,479 breast 
cancer patients undergoing mastectomy were audited in the UK National Mastectomy and 
Breast Reconstruction (NMBR) audit
(2)
, where 4796 (31%) underwent breast reconstruction. 
 
The loss of a breast adversely affects a range of patient-reported outcomes (PROs), which may 
be considered multidimensional aspects of a woman’s health-related quality of life (HRQL)
(3-5)
. 
The pedicle latissimus dorsi (LD) or “back flap” procedure involves transferring muscle, fat and 
skin to the chest wall and is commonly used
(2, 5)
.  The autologous tissue LD (ALD) procedure 
involves an extended donor/back site dissection of tissues potentially avoiding an implant
(5)
. 
The implant-assisted LD reconstruction (LDI) minimises the extent of donor site dissection 
using an implant to achieve the desired volume
(5)
. Current evidence does not support the 
superiority of either type of LD procedure in terms of PROs
(2, 3, 6)
. Clinicians may favour 
immediate autologous procedures when post-mastectomy radiotherapy (PMRT) is predicted 
pre-operatively. This is based on studies suggesting superior cosmetic outcomes, although 
there is poor evidence comparing this approach to delayed procedures
(2, 3, 5-8)
. 
 
The NMBR audit, that assessed PROs from 3- to 18-months using the BREAST-Q breast 
reconstruction questionnaire
(9)
. The most commonly reported adverse effects on PROs were 
physical and functional difficulties with the shoulder girdle and abdomen (34% reported 
difficulties most or all of the time); dissatisfaction with the reconstructed breast (40%) and 
donor site (15-30%); general pain and psychosocial difficulties ranging from 15-40%
(10)
. In the 
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 5 
current study, the European Organisation for the Research and Treatment of Cancer (EORTC) 
core PRO questionnaire (QLQ-C30) was used
(11)
 supplemented by the breast-specific module 
(QLQ-BR23)
(12)
 and the Functional Assessment of Cancer Therapy-Breast Cancer scale (FACT-
B)
(13)
. While these questionnaires address wide-ranging issues relevant to women with breast 
cancer, they do not cover issues specific to breast reconstruction. Therefore, an EORTC breast 
reconstruction module was recently developed
(14)
.  
 
A systematic review of PROs after breast reconstruction showed no clinical trials and only a 
few prospective longitudinal cohort studies (4 out of a total of 11) that reported PROs up to 24-
months after reconstruction
(3)
. None of the prospective cohort studies evaluated the effects of 
PMRT on PROs
(3)
, although PMRT may confer a survival benefit when combined with systemic 
adjuvant therapies
(15, 16)
. Increasingly, there is a reliance on methodologically robust cohort 
studies for evidence on the comparative effectiveness of different types of reconstructions, 
where randomized trials are challenging
(17, 18)
. There is no consensus in the literature regarding 
the impact and duration of breast reconstruction effects on PROs
(3)
. Despite the known clinical 
efficacy of both types of LD breast reconstructions, there is a paucity of information on the 
effect-sizes of core PRO domains in all studies
(3, 8)
.  
 
This paper reports on an ongoing multi-centre cohort study. We have previously reported PROs 
12 months post-operatively
(8)
. The aims of the current paper are to evaluate: effect-sizes for 
change from baseline (pre-operative) at 2- and 3-years post-operatively on all PRO domains of 
two common types of breast reconstructions; which baseline factors are predictive of PRO 
domain scores at 2- and 3-years; which PRO domains are most sensitive to demonstrating 
changes over time; and what differences exist between LDI and ALD groups in PRO scores at 2- 
Page 5 of 31
http://mc.manuscriptcentral.com/bjs
BJS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
FOR REVIEW ONLY
 6 
or 3-years after adjusting for clinico-demographic case-mix. This study aims to generate 
hypotheses and provide estimates of domain effect-sizes to guide subscale selection within 
PROs and sample-size calculation for future studies
(19)
.  
 
 
METHODS 
Study design, quality control and risk of bias:  
This study was developed as a protocol-driven prospective design
(18)
. Several clinical risk 
factors potentially biased the comparison of PROs in ALD versus LDI reconstructions, as higher 
risk breast cancer patients were more likely to have poorer PROs at diagnosis consequent to 
more aggressive treatments
(4, 8)
. It is this clinically higher risk group that was more likely to be 
recommended for immediate ALD rather than LDI reconstructions
(8, 15)
. These clinical risk 
factors were assessed and compared between ALD and LDI groups at baseline, and adjusted 
for in regression analyses of PROs. All missing data (PROs and clinical) was accounted for 
(Figure 1).  
 
Study sample:  
This paper describes the extended follow up (January 2007 to May 2013) of a multi-centre 
prospective longitudinal cohort study ethically approved (National Research Ethics Committee 
Wiltshire: 05/Q2008/14) and conducted in six UK centres (Bristol, Cambridge, Glasgow, Hull, 
Swindon and York). Eligibility criteria have been previously described
(8)
. These included women 
with early breast cancers (Stages I-II) in one or both breasts, and excluded women with 
previously diagnosed breast cancers, confirmed metastatic disease and recommended for 
delayed breast reconstructions
(8)
.  
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 7 
Detailed study processes have been described relating to: clinical diagnosis; local 
multidisciplinary team decision-making regarding PMRT recommendations; dual localisation 
sentinel lymph node biopsy and magnetic resonance imaging according to clinical guidelines
(8, 
15)
. Women who consented then self-reported questionnaires prior to mastectomy and breast 
reconstruction (baseline) at their pre-operative assessment clinic, and were subsequently 
posted their 2- and 3-year post-reconstruction questionnaires using a self-addressed envelope. 
Two postal reminders prompted patients to return their questionnaires. Recurrent (local or 
distant) disease did not exclude questionnaire administration, except in the case of cerebral 
metastases.  
 
Primary endpoints:  
Four PRO questionnaires were used to evaluate the levels of change (expressed as the mean 
change from baseline at 2- and 3-years post-operatively divided by the standard deviation of 
change, i.e. ‘effect-size’) on patient-reported symptom and functioning over time after 
immediate ALD or LDI reconstructions treated with PMRT or no PMRT. The EORTC core quality 
of life questionnaire, QLQ-C30, was used to assess core PRO domains of quality of life 
(functioning and symptoms)
(11)
, alongside the breast cancer module, QLQ-BR23, to evaluate 
breast and arm symptoms, sexual functioning and body image
(12)
. The Hospital Anxiety and 
Depression Scale (HADS), distinguishing anxiety and depression, was also used
(20)
.  FACT-B was 
used to assess physical, social, emotional and functional well-being
(13)
. Items within each 
subscale of each PRO were summed and transformed to a range of 0 to 100
(12, 13)
. For body 
image, functioning and well-being scales, higher scores were indicative of better outcomes; 
positive change indicated improvement and negative change indicated worsening. In contrast, 
for symptom scales (breast, arms, pain and fatigue), anxiety and depression, higher scores 
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 8 
were indicative of worse outcomes; positive change indicated worsening and negative change 
reflected improvement
(12, 13)
. Selection of these PROs was based on previously reported PRO 
studies; with no validated breast reconstruction-specific questionnaires at the time this study 
was designed
(8, 19, 21)
. In the Michigan Breast Reconstruction Outcomes Study (MBROS), these 
PROs showed significant differences in mean scores after types of immediate and delayed 
breast reconstruction
(19, 21)
.  
 
Secondary endpoints:  
Patient’s compliance rates for completion of PROs were documented (Figure 1). Adverse 
clinical events were graded using the Dindo-Clavien classification
(22)
. Early surgical 
complications were recorded up to and including 3-months after breast reconstruction, 
compared to late complications occurring between 4-months to 3-years. Loco-regional 
recurrence and distant metastatic disease were assessed using established criteria
(23)
.  
 
Clinical and demographic characteristics:  
Clinical Report Forms (CRFs) were used to record all clinical details as described including 
socio-demographic factors
(8)
 (Table 1). Additional surgeries (complications or cosmetic 
procedures) were documented over 3-years. Annual clinical follow-up occurred on or close to 
the anniversary date of breast reconstruction.  
 
Statistical analysis:  
As this was primarily a hypothesis-generating study, the sample size was based on obtaining 
sufficient numbers of women in the main treatment groups of interest to provide reasonably 
reliable estimates of effect-size for all domains/subscales within the selected PROs. The 
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 9 
purpose of these preliminary effect-size estimates was to guide PRO domain selection and 
sample size calculation for future studies
(24, 25)
. At the time of analyses for this paper, the total 
sample was sufficiently powered to evaluate relatively small effect-sizes (0.3) for intra-group 
changes from baseline to 2-years (87% power) and 3-years (76%) in the pooled surgical groups, 
and moderate effect-size changes (0.5) within each reconstruction group (ALD, LDI separately) 
(>95% power at 2 years, >75% at 3 years). It was somewhat underpowered to detect moderate 
effect-size differences between ALD and LDI groups at 2-years (68% power) and more so at 3-
years (54%). Cognizant of the large number of p-values generated, a cut off of p<0.01 was used 
to indicate statistical significance. All analyses were performed using the R-program version 
2.15.1 (The R Foundation for Statistical Computing, Bell Laboratories, Lucent Technologies, 
USA). No imputation of missing values was made and each result was based on all patients for 
whom relevant data were recorded.  
 
Baseline clinical and socio-demographic data were compared between the two surgical groups. 
Categorical variables, summarised as proportions, were compared using the Chi square test or 
Fisher's exact test.  Continuous data, summarised using the mean and standard deviation or 
the median and range where distributions were non-normal, were compared using the 
Student's t-test or the non-parametric rank sum test. 
 
Mean domain score changes from baseline (pre-operative) to 2- or 3-years were calculated 
within the whole sample (Table 2) and within each surgical group (Figure 2).  Effect-sizes were 
measured by Cohen’s d
(26)
. The clinical significance of effect sizes for the QLQ-C30 and FACT-G 
data were interpreted using evidence-based guidelines
(24-27)
.  As similar guidance is lacking for 
the other PROs, general guidance was used whereby an effect-size less than about 0.3 was 
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 10
considered ‘small’ but clinically relevant
(26, 27)
, and effect-sizes exceeding about 0.5 were 
referred to as ‘moderate’ and considered ‘unequivocally clinically important’, and finally effect-
sizes of larger than 0.8 were  called ‘large’
(24-27)
. 
 
Longitudinal analysis of PROs at 2- and 3-years was done by fitting a separate generalized 
estimating equations model for each PRO domain, including the corresponding baseline PRO 
value as a covariate to improve precision of estimates of other predictors (Figure 3). Each 
model included the following baseline variables as potential predictors: type of reconstruction, 
PMRT, chemotherapy (adjuvant or neo-adjuvant), age at operation (50 years and over, or 
under 50 years), early (up to 3-months) and late complications (4-months to 3-years) for each 
PRO domain. The contribution of each baseline parameter to predicting each PRO domain was 
measured by the p-value of the corresponding regression coefficient. Since P-values do not 
indicate the direction of an effect, each was converted to a Z-score
(27)
 (e.g. p-value of 0.05 
converts to a Z score of ±1.96).   
 
A second multiple linear regression model (supplementary data not shown) was used to 
generate case-adjusted estimates of differences between LDI and ALD groups in PRO changes 
at 2- and 3- years. In these models, the main predictor of interest was type of surgery. 
Covariates included were: baseline PRO value (to improve precision, as above); and each 
variable in Table 1 (body mass index, chemotherapy, tumour size, margin positivity, lymph 
node positivity, PMRT and late complications) that differed between surgical groups at 
baseline (p<0.10 to be inclusive of all potential confounders). Type of axillary surgery was 
omitted as it was considered a surrogate for lymph node positivity. Given the large number of 
covariates, the Holm-Bonferroni allowance was used to adjust for multiple testing.  
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 11
RESULTS 
Study sample characteristics:  
Two hundred and forty patients were prospectively screened at multidisciplinary meetings, 
with recruitment of 206 (86%) women undergoing immediate LD BRRs. These comprised 93 
(45%) LDI procedures and 113 (55%) ALD reconstructions (Figure 1). The proportions of women 
undergoing ALD reconstructions were often in keeping with the clinician’s perception of the 
likelihood for PMRT
(6)
. The extent to which this decision-making materialised into 
administering PMRT was not recorded in this study. Compared with women who had LDI 
procedures, those who had ALD reconstructions had significantly higher body mass indices, 
larger tumors, greater likelihood of lymph node positivity and treatment with neo-adjuvant or 
adjuvant chemotherapy as well as PMRT (Table 1).  Thirty percent of women had undergone a 
recent therapeutic wide local excision, which subsequently required completion mastectomy 
based on microscopic margin positivity. The significantly greater margin positivity rate of 25% 
for invasive disease in the LDI group, compared with 7% in the ALD group, is largely 
inexplicable and would necessitate consideration of PMRT
(15)
. Details regarding particular 
contributors to margin positivity were not determined. There were no other significant 
differences in pathological characteristics between the surgical groups (data not shown)
(8)
. 
There were 16 patients with bilateral breast cancers, but only one was included due to missing 
data. As previously reported, women undergoing ALD reconstructions more frequently 
received axillary lymph node dissections while those who had LDI surgeries had lesser axillary 
procedures
(8)
. Previously reported clinico-pathology and socio-demographic characteristics 
were similar between the surgical groups (data not shown)
(8)
. One of the 78 women who had 
LDI reconstructions developed a local recurrence and five of the 104 women undergoing ALD 
procedures developed distant metastases. 
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PRO questionnaire completion and missing data rates (Figure 1):  
Of 206 recruits, 182 (88%) women completed baseline questionnaires as a study prerequisite: 
157/182 (86%) completed at 1-year (data published elsewhere)
(8)
; 157/182 (86%) at 2-years 
and 122/182 (67%) at 3-years. Reasons for missing data included patient non-compliance and 
administrative issues. Patient’s compliance rates for questionnaire completion were 
consistently high: 91% at baseline, 92% at 2-years and 87% at 3-years. Logistical and 
administrative issues were: questionnaires not sent out and missing clinical data from CRFs.  
 
Surgical complications (Table 1):  
As previously reported
(8)
, early complications of the breast and/or donor site comprised: 
hematoma, infection, skin necrosis, fat necrosis, and wound dehiscence. Implant-related 
complications and others were also recorded. Additional donor site complications comprised 
persistent seromas (arbitrarily defined as 5 or more outpatient aspirations) and back pain.  
There were no differences between surgical groups regarding early complications. 
 
Long-term complications included: capsular contracture and implant complications, breast 
lymphoedema, restricted movement of shoulder girdle, back symptoms, lymphoedema of the 
arm, and cosmetic issues. Although long-term complications between surgical groups did not 
differ, there was a trend to more grade 2 and 3 complications
(22)
 after ALD reconstructions. 
 
Long-term effects on PROs after immediate breast reconstruction (Table 2):  
Table 2, presents the mean baseline levels of PROs and mean domain score change from 
baseline at 2- and 3-years post-breast reconstruction within both ALD and LDI groups. These 
results demonstrated statistically significant and clinically important gains in a number of 
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 13
psychosocial functioning scales (EORTC QLQ-C30: emotional and social functioning, and FACT-
B: emotional and functional well-being scales), and reductions in depression (HADS), with 
overall improvements in quality of life (total FACT-B) at 3-years
(24-27)
. However, long-term 
deteriorations, also statistically significant and clinically important, occurred in physical 
function (QLQ-C30), body image (QLQ-BR23) and social wellbeing (FACT-B) at both time points. 
In contrast to the emotional gains noted above, the HADS anxiety scale detected persistent 
anxiety at 2- and 3-years, respectively
(24-27)
.  
 
PRO effect-size and direction of effects for types of LD breast reconstruction at 2 and 3 years 
(Figure 2 and Supplemental material):  
The mean changes in levels of PROs from baseline to 2- and 3-years in each surgical group 
(Figure 2) are shown with the effect-size threshold of 0.5 (+/-) standard deviations indicating 
unequivocal clinical significance
(27)
. This univariate analysis provides important clinical insights 
into women’s experiences in the two reconstruction groups, and the PRO effect-sizes facilitate 
interpretation of their magnitude and direction. There were no statistically significant 
differences in change in PRO levels between the two types of breast reconstruction. 
 
For each breast reconstruction type, there were clinically unequivocal changes in PROs from 
baseline levels at 2-years (Figure 2A), with the ALD group experiencing notable improvements 
in breast symptoms, but worsened physical function and arm symptoms. In contrast, the LDI 
group experienced improved levels of depression and functional well-being.  
 
At 2-years, despite both reconstruction groups experiencing clinically unequivocal 
improvements in emotional function and well-being, women also experienced heightened 
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anxiety and reductions in body image and social well-being (all with clinically significant effect-
sizes). Notable reductions apparent in social well-being at 2-years, persisted at 3-years. Social 
well-being includes issues such as feeling close to partner and friends, and getting support 
from family and friends that arguably may relate to body image problems. By 3-years (Figure 
2B), both groups experienced notable improvements in breast symptoms, and while there 
were large (effect size of about 0.8) improvements in emotional function and well-being, both 
groups were also experiencing clinically unequivocal (effect size of about 0.5) levels of anxiety, 
likely related to fear of cancer recurrence
(24-27)
. Levels of anxiety were greater in the ALD 
group, consistent with worse prognostic factors compared to the LDI group, with continued 
worsening anxiety from 2- to 3-years in both groups.  
 
Importantly, reductions in body image persisted at 3-years only in the LDI group, who also 
experienced considerable reductions from baseline in sexual function at 3-years. Women 
undergoing ALD procedures experienced improved overall quality of life at 3-years through 
increased total FACT-B scores (small effect-size) and functional wellbeing (moderate effect-
size), despite worse physical function (small effect-size) and increased arm symptoms 
(moderate effect-size) at this time
(24-27)
. This descriptive data provide information about the 
responsiveness of PRO subscales /domains in evaluating these surgical procedures.  
 
Multivariate analyses of baseline predictors on long-term PROs (Figure 3):  
Some clinical and demographic characteristics were independent predictors of PROs in 
multiple regression analyses with 2- and 3-year results alongside those reported at 1-year
(8)
. 
Women receiving PMRT showed deteriorations in the QLQ-C30 social functioning domain (Z 
score: -3.113, p=0.002) at 2-years, resolving at 3-years. There were no significant effects of 
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chemotherapy at 2-years, but worse EORTC QLQ-BR23 arm symptoms at 3-years (Z score: 
2.860, p=0.005). Younger women reported significantly worse FACT-B physical well-being (Z 
score: -2.820, p=0.006). The types of LD breast reconstruction surgery did not independently 
predict any of the PROs at 2-years, and only one at 3-years, where an immediate ALD breast 
reconstruction was associated with significantly improved sexual functioning (Z score: 3.075, 
p=0.003) relative to LDI procedures. 
 
Trends to significance for Z scores (0.01<p≤0.05) were seen (data not shown) where: PMRT 
was associated with increased EORTC QLQ-BR23 arm symptoms after (2-years); chemotherapy 
was associated with worse EORTC QLQ-C30 physical functioning (2-years), FACT-B breast 
cancer subscale (2- and 3-years) and total FACT-B score (3-years); younger women experienced 
poorer EORTC QLQ-C30 role functioning (2-years) and total FACT-B score (3-years). Somewhat 
paradoxically, early surgical complications were associated with reduced depression (2-years), 
whilst late complications were associated with improvements in FACT-B social and emotional 
well-being (2-years), potentially reflecting increased clinical interactions
(28)
. There were no 
significant differences between the reconstruction types in PRO changes at 2- and 3-years, 
respectively in a second regression model adjusted for case-mix (data not shown), with the 
exception of an interesting finding of improved sexual functioning after ALD procedures (Z 
score 2.792, P=0.0067). 
 
 
DISCUSSION 
This study expands on the PRO 12-month follow-up data
(8)
 (Figure 3), and evaluates changes in 
a wide range of PRO domains at 2- and 3-years in terms of effect-sizes, for each type of breast 
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reconstruction. The EORTC and FACT questionnaires proved complimentary, and should not be 
regarded as substitutable
(29)
. These results are novel, with no previous publications or the 
NMBR audit specifically describing effect-sizes for relevant PRO domains over this time 
period
(3, 8, 19, 21)
. Our analyses were sufficiently powered to demonstrate that regardless of 
whether immediate breast reconstruction was autologous or implant-assisted, it produced 
significant long-term gains in psychosocial functioning and reductions in depression relative to 
pre-operative (baseline) PRO domain scores (Figure 2). Despite this, however, notable 
deteriorations in physical function, body image and social well-being persisted at 2- and 3-
years post-reconstruction.  However, this study had insufficient power to detect differences 
between surgery types, with some tantalising differential patterns warranting further 
investigation in larger samples. This study has therefore generated hypotheses about the 
specific PRO domains that differ over time, and provides good effect-size estimates on which 
to base sample size calculations and selected PRO outcomes for a well-powered study.  
 
This study affirms the effects of known clinical characteristics on long term PROs in women 
undergoing immediate reconstructions. Regression analyses showed three independent 
adverse predictors on PRO subscales: PMRT, chemotherapy and young age (Figure 3). PMRT, a 
likely surrogate for biologically aggressive breast cancers, was associated with significantly 
impaired social functioning at 2-years. Likewise, chemotherapy and young age may be 
surrogates for more aggressive disease adversely affecting arm symptoms and physical 
wellbeing, at 3-years. Autologous immediate breast reconstruction (ALD) significantly 
improved sexual functioning at 3-years independent of other clinical and demographic 
variables, with no other long-term PRO effects by type of surgery. In keeping with CONSORT-
PRO reporting standards, establishing the effect-sizes and independent significance of core 
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PRO domains from disease-specific and surgery-specific questionnaires is crucial in the future 
selection of primary outcomes measures in all study designs
(30)
.  
 
A Cochrane systematic review showed inadequate reporting of psychosocial functioning after 
immediate breast reconstructions
(31, 32)
. The time-points and level at which psychosocial 
outcomes stabilise are unknown. In the NMBR audit, only the proportion of women (20-40%) 
with psychosocial issues at 18-months after immediate reconstructions was reported with no 
results on effect-sizes
(10)
. This study doubles the follow-up time of the NMBR audit to 3-years. 
There were distinct differences between QLQ-C30’s social functioning and FACT-B’s social well-
being in this study
(29)
. The former, which assesses impacts on social activities and family life, 
showed a significant improvement at 2-years after all reconstructions (Table 2 and Figure 2), 
with no effects by 3-years. By comparison, FACT-B’s social well-being, which evaluates 
impaired social support and relationships, deteriorated significantly after ALD and LDI at 2- and 
3-years, respectively. Consistent with our study, the Michigan breast Reconstruction Outcomes 
Study (MBROS) cohort reported a significant (p=0.0099) decline in social well-being (FACT-B) at 
2-years after immediate breast reconstruction
(19)
. However, the MBROS cohort omitted 
patients’ clinical characteristics and adjuvant treatments making contextual comparisons with 
this study difficult
(19)
. In our previous publication
(8)
, the adverse effects of chemotherapy 
(p=0.001) and early complications (p=0.001) on social well-being at 1-year notably dissipated at 
2- and 3-years (Figure 3). 
 
This study showed significantly worse sexual function (EORTC QLQ-BR23) after LDI procedures, 
at 3-years. Other studies have not detected differences in sexual functioning either by type of 
breast reconstruction or by extent of breast surgery
(4, 19)
. While the MBROS cohort did not 
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evaluate sexual functioning or validated body image items
(19)
, it used a study-specific 
questionnaire that showed significantly improved body image at 2-years after autologous 
procedures compared to implant-based reconstructions
(19)
. Restoration of a women’s body 
image after mastectomy by immediate reconstruction was less than expected in both the 
MBROS cohort
(19)
, including another large (n=2000) cohort study on sexuality
(4)
, and in our 
data. Surprisingly, mastectomy with breast reconstruction negatively impacted on a somewhat 
greater proportion (45%) of women’s sex lives compared to 41% after mastectomy alone
(4)
. 
Although the EORTC QLQ-BR23 body image subscale showed dramatic intra-group reductions 
at 2-years in this study, only sexual function (EORTC QLQ-BR23) remained a significant 
independent factor (regressions) affecting quality of life over time compared to body image at 
3-years (Figure 3). The significant improvements (p<0.0001) in general mental health and the 
role emotional subscale (Short Form (SF)-36) at 2-years in the MBROS cohort
(19)
, is similar to 
the dramatic increases in emotional functioning and well-being in this study at 2- and 3-years.  
However, we also observed clinically significant heightened anxiety from baseline to 2- and 3-
years with moderate effect-sizes, more so after ALD procedures, potentially reflecting concerns 
about cancer recurrence.  
 
Consistent with Roland et al
(4)
, and King et al
(33)
, our 1-year results show younger women fare 
worse that older women across a spectrum of PRO domains; in our study these were social 
functioning (p=0.02), body image (p=0.02) and anxiety (p=0.01)
(8)
. The current analyses 
demonstrate the value of longer-term follow-up by showing that these problems had resolved 
by 2- and 3-years (Figure 3). However, physical wellbeing (FACT-B) had become significantly 
impaired at 3-years (p=0.006). The observation that significantly worse arm symptoms (EORTC 
QLQ-BR23) were associated with PMRT at 2-years and chemotherapy at 3-years is likely a 
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reflection of more aggressive disease meriting extensive treatments, rather than direct 
causation by the latter (Figure 3).  The somewhat paradoxical observation at 2-years of 
associations of early surgical complications with reduced depression, and late complications 
with improvements in FACT-B social and emotional well-being, may be explained by potentially 
increased clinical interactions enhancing patient doctor communications and hence PROs
(28)
. 
 
Specific strengths of this study are the pre-surgery baseline assessment of PROs and a good 
coverage of clinical and demographic variables
(18)
. Uniquely, it integrates surgical complications 
and long-term effects of adjuvant treatments, particularly PMRT. Despite a prospective design, 
there remain methodological limitations of missing data. Cohort studies would benefit from 
similar operational funding and research infrastructure within clinical trials. The majority of 
cohort studies in breast reconstruction report 12-month data only
(3)
, where this study informs 
longer-term outcomes, and value-adds by extending our knowledge of the evolution and 
resolution of PROs. Some biases may remain un-adjusted for through unmeasured 
characteristics, but we assessed all known potential predictors (Table 1 and Figure 3). Our 
sample size was underpowered for intergroup comparisons by different types of breast 
reconstruction. Despite it’s limited sample size, this paper provides preliminary indications of 
the PRO domains that may differ by each reconstruction group, and preliminary estimates that 
can be used to determine sample sizes for future studies designed to test the hypotheses 
generated by the results in this paper. Furthermore, the suite of PROs used may not be 
responsive to all breast reconstruction surgery-specific effects on PROs.  
 
As this study commenced prior to phase 4 validation of the BREAST-Q, it remains for future 
studies to evaluate the psychosocial and sexual well-being domains of the BREAST-Q on these 
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specific reconstructions
(9)
. Currently, there are no other known studies evaluating the long-
term effect-sizes of the BREAST-Q domains on which to base any meaningful comparisons with 
the findings described. The recently developed and phase 3 validated EORTC breast 
reconstruction (BRR) validated questionnaire has the advantages of being used alongside the 
EORTC QLQ-C30 and QLQ-BR23 in breast cancer patients
(14)
 and could provide future 
confirmation of these findings. This study underlines the importance of identifying core PRO 
subscales /domains such as those from the EORTC QLQ-C30, FACT-B and HADS to be used 
alongside the future EORTC BRR surgery questionnaire
(14)
. Definitive studies investigating the 
differential effects of types of breast reconstruction can use our findings to frame ‘a priori’ 
hypotheses about the size and direction of expected effects, and determine sample sizes 
required to detect them with confidence
(30)
.  
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Table 1: Comparison of baseline clinical, demographical and pathological characteristics in women 
having immediate implant-assisted (LDI) or autologous latissimus dorsi (ALD) breast reconstruction 
 
Values in parentheses are percentages unless indicated otherwise; **values are median (range) and 
*values are mean (SD). ***Dindo-Clavien classification of surgical complications
(22)
. ****Margin 
positivity at mastectomy. Abbreviations: LDI, implant-assisted latissimus dorsi breast reconstruction; 
ALD, autologous latissimus dorsi breast reconstruction; SLNB, sentinel lymph node biopsy; DCIS, 
ductal carcinoma in situ; Grd., Grade of surgical complications by Dindo-Clavien
(22)
.  
‡Statistical tests: 
¶
Student’s t-test; 
§
Fisher’s exact test and 
π
Chi square test.  
Baseline patient characteristics 
 
LDI (n = 78) 
 
ALD (n = 104) P
‡
 
Age  (years)** 50 (22-70) 50.5 (25-68) 0.425
¶
 
Body mass index (kg/m
2
)* 25.1 (4.3) 27.4 (4.9) <0.001
¶
 
Neoadjuvant chemotherapy No 76     (97) 91 (88) 0.026
§
 
Yes 2       (3) 13 (13) 
Presenting diagnosis Screen-detected 38     (49) 42 (40) 0.293
§
 
 Symptomatic 40     (51) 62 (60) 
 
 
Type of axillary surgery 
None 5        (6) 6    (6)  
0.021
π
 
 
Previous axillary surgery 3        (4) 4    (4) 
SLNB 20     (26) 24 (23) 
Axillary lymph node sample 14     (18) 18 (17) 
Axillary clearance 36     (46) 52 (50) 
Tumour size (mm)* 16.6  (15.7) 23.7 (20.4) 0.016
¶
 
Multi-focal /-centric No 35/73 (48) 50/103 (49) 1.000
§
 
Yes 38/73 (52) 53/103 (51) 
Lymphovascular invasion No 52/72 (72) 63/100 (63) 0.447
§
 
Yes 20/72 (28) 37/100 (37) 
 
Margin positivity (<1mm) 
Invasive 18/73 (25) 7/103   (7) 
<0.001
π
 
DCIS 13/56 (23) 11/61 (18) 
0.488
π
 
Lymph node positivity No 59       (76) 62   (60) 0.027
§
 
Yes 19       (24) 42   (40) 
Adjuvant chemotherapy No 49       (63) 46   (44) 0.030
§
 
Yes 29       (37) 58   (56) 
Adjuvant radiotherapy No 62       (79) 58   (56) <0.001
§
 
Yes 16       (21) 46   (44) 
Early Complications 
(0-3 months) 
No 29/76  (38) 47/97  (48)  
0.217
§
 Yes (Grd. 1) 21/76  (28) 19/97  (20) 
Yes (Grd. 2 to 3)
***
 26/76  (34) 31/97  (32) 
Late Complications  
(4-36 months) 
No 19/76  (25) 38/99  (38)  
0.074
§
 Yes (Grd. 1) 46/76  (61) 28/99  (28) 
Yes (Grd. 2 to 3)
***
 11/76  (15) 33/99  (33) 
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Table 2: Pre-operative (baseline) and post-operative (2 years and 3 years) Health Related Quality of Life (HRQL) domain 
scores, and change at 2 and 3-years, in all patients with immediate types of LD breast reconstructions (ALD and LDI) 
 
 
 
 
Abbreviations: ALD, autologous latissimus dorsi; LDI, implant-assisted latissimus dorsi; HRQL, Health-Related Quality of 
Life; n, median number of respondents and (range); EORTC QLQ, European Organisation for the Research and Treatment 
of Cancer Quality of Life Questionnaires; HADS, Hospital Anxiety and Depression Scale; FACT-B, Functional Assessment 
of Cancer Therapy-Breast. S.D., Standard Deviation. P <0.01 (Bold) indicates a statistically significant mean score change 
from baseline at 2- and 3-years with positive or negative (-) directions of change
(24-26)
. Mean score changes considered as 
clinically relevant comprised large scale changes of -3 to 3; 2 represented medium and 1 represented small
(24,25, 27)
. Data 
for effect Sizes are not shown here for the overall group, but for each type of breast reconstruction (Figure 2 and 
supplemental material)
(26)
. 
 
 
 
HRQL subscale 
Baseline 
Median 
n=175 
(167- 182) 
2 years 
Median 
n=154 
(143-155) 
HRQL change over 2 years 
Median n=123 
(135 -155) 
3 years 
Median 
n=148 
(114-124) 
HRQL change over 3 years 
Median n=117 
(107-124) 
Mean score Mean score Mean change 
(SD) 
p-value Mean score Mean change 
(SD) 
p-value 
EORTC QLQ-C30 and QLQ-BR23 
Global QoL 75.7 75.4 -0.61 (20.9) 0.720 77.6 2.45 (20.3) 0.191 
Physical Function 94.8 89.7 -5.30 (15.1) <0.001 90.3 -4.90(15.7) <0.001 
Role Function 87.5 88.6 0.55 (29.1) 0.816 87.1 -2.89(28.4) 0.264 
Emotional Function 67.1 80.4 11.97 (23.3) <0.001 82.1 14.27(24.4) <0.001 
Social Function 83.4 89.5 5.07 (24.5) 0.013 90.1 5.70 (25.3) 0.016 
Pain 12.6 15.3 3.75 (22.7) 0.044 16.1 4.68 (24.3) 0.036 
Fatigue 21.8 21.5 0.11 (24.9) 0.957 20.5 0.51 (25.9) 0.831 
Breast Symptoms 15.4 8.6 -6.78 (18.2) <0.001 8.3 -7.36(18.1) <0.001 
Arm Symptoms 8.0 12.3 3.56 (16.9) 0.012 13.1 4.95 (18.0) 0.004 
Sexual Function 69.5 66.6 -2.47 (29.8) 0.338 66.5 -1.40(28.6) 0.613 
Body Image scale 82.8 74.0 -8.91 (26.9) <0.001 76.9 -7.30(26.4) 0.004 
FACT-B 
Physical Wellbeing 24.7 24.6 -0.24 (5.2) 0.566 24.9 0.02 (5.3) 0.967 
Social Wellbeing 24.6 22.8 -2.00 (4.8) <0.001 22.5 -2.38 (4.9) <0.001 
Emotional Wellbeing 16.1 19.3 3.12 (6.0) <0.001 19.5 3.63 (4.8) <0.001 
Functional Wellbeing 20.5 22.1 1.62 (6.7) 0.003 22.1 1.46 (6.4) 0.016 
Breast Cancer Subscale 26.0 26.3 -0.15 (6.6) 0.780 26.9 0.29 (5.9) 0.604 
FACT-B Total 107.6 114.3 5.80 (30.0) 0.017 115.5 7.93 (26.8) 0.001 
HADS 
Anxiety 10.7 11.9 1.08 (3.0) <0.001 12.2 1.51 (2.8) <0.001 
Depression 9.1 8.6 -0.59 (1.7) <0.001 8.5 -0.55 (1.8) 0.001 
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Appendix 1: Pre-operative (baseline) and post-operative (2- and 3-years) Health Related Quality of Life (HRQL) domain scores and change at 2- and 3-years in 
patients with immediate ALD breast reconstructions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complete data set for Figures 2A and B. Abbreviations: ALD, autologous latissimus dorsi breast reconstruction; HRQL, Health-Related Quality of Life; N, number; EORTC QLQ, 
European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaires; QoL, quality of life; FACT-B, Functional Assessment of Cancer Therapy-Breast; 
HADS, Hospital Anxiety and Depression Scale. S.D., Standard Deviation. P <0.01 (Bold) indicates a significant mean difference in scores from baseline with positive or negative (-) 
directions of effects. CI indicates 95% confidence intervals. Effect-sizes (ES) measured by Cohen’s d statistic defined as the difference between two means divided by the pooled 
standard deviation where <0.2 indicates a ‘trivial’ ES, 0.2-0.5 indicates a ‘small’ ES, 0.5-0.8 indicates a ‘medium’ ES and larger than 0.8 indicates a ‘large’ ES
(24-27)
.  
HRQL Subscale Baseline       2 years         HRQL Change over 2 years     3 years    HRQL Change over 3 years 
n Mean 
Score 
n Mean 
Score 
n Mean 
change 
S.D. Effect- 
size 
p-value 95% CI n Mean 
Score 
n  Mean 
 change 
S.D Effect-  
size 
p-value 95% CI 
EORTC QLQ-C30 and QLQ-BR23 
Global QoL 99 76.5 88 75.8 84 -1.49 22.0 -0.068 0.537 -0.286     0.150 74 78.2 70 2.26 17.5 0.129 0.283 -0.110     0.368 
Physical Function 101   95.0    88 88.6 85 -6.98 16.0 -0.436 <0.001 -0.635    -0.219 74 89.4 72 -6.48 16.2 -0.399 0.001 -0.635    -0.163 
Role Function 101 85.8 88 88.4 85 1.18 31.8 0.037 0.734 -0.180     0.254 74 86.9 72 -2.55 26.3 -0.097 0.415 -0.333     0.139 
Emotional Function  98 67.4 88 81.5 83 12.05 23.5 0.513 <0.001 0.293       0.733 74 84.0 69 17.31 21.8 0.794 <0.001 0.533       1.053 
Social Function 97 82.8 88 88.8 82 4.47 26.5 0.169 0.130 -0.052     0.390 74 89.9 68 6.13 25.1 0.244 0.048 0.002       0.486 
Pain 101 15.0 88 15.9 85 2.94 24.7 0.119 0.275 -0.098     0.336 74 18.0 72 5.09 25.0 0.204 0.088 -0.032     0.440 
Fatigue 101 22.1 88 22.2 85 1.37 25.7 0.053 0.624 -0.164     0.270 74 21.5 72 2.24 24.6 0.091 0.443 -0.145     0.327 
Breast Symptoms 96 17.2 88 7.1 81 -9.57 18.9 -0.506 <0.001 -0.728    -0.284 73 9.7 66 -6.57 19.9 -0.330 0.009 -0.576     0.084 
Arm Symptoms 96 8.0 88 14.6 81 5.83 16.0 0.365 0.001 0.143       0.587 73 14.8 66 7.49 16.8 0.446 0.001 0.200       0.692 
Sexual Function 93 70.4 79 69.0 73 0.00 31.5 0.000 1.000 -0.234     0.234 66 73.0 62 3.76 29.6 0.127 0.321 -0.127     0.381 
Body Image scale 97 83.8 88 76.3 81 -8.02 24.5 -0.328 0.004 -0.550    -0.106 73 79.2 67 -4.73 23.0 -0.206 0.097 -0.450     0.038 
FACT-B 
Physical Wellbeing 99 24.5 88 24.5 83 -0.29 5.7 -0.052 0.639 -0.272     0.168 74 24.7 70 -0.28 5.8 -0.048 0.691 -0.287     0.191 
Social Wellbeing 100 24.8 88 22.8 84 -2.35 5.0 -0.467 <0.001 -0.685    -0.249 74 22.5 71 -2.48 5.3 -0.468 <0.001 -0.706    -0.230 
Emotional Wellbeing 98 16.3 88 19.7 83 3.26 6.7 0.486 <0.001 0.266       0.706 74 19.7 69 4.11 5.0 0.821 <0.001 0.581       1.061 
Functional Wellbeing 98 20.4 88 21.8 83 1.24 6.9 0.179 0.106 -0.041     0.399 74 22.3 69 1.99 5.9 0.334 0.007 0.094       0.574 
Breast Cancer Subscale 98 25.8 88 25.8 82 -0.56 6.0 -0.093 0.404 -0.314     0.128 73 26.4 69 -0.15 5.1 -0.030 0.804 -0.270     0.210 
FACT-B Total 104 106.1 89 113.4 89 6.37 35.6 0.179 0.095 -0.033     0.391 74 115.2 74 8.89 26.9 0.330 0.006 0.098       0.562 
HADS 
Anxiety 99 10.7 88 12.2 83 1.24 3.0 0.421 <0.001 0.201       0.641 71 12.3 68 1.76 2.9 0.614 <0.001 0.372       0.856 
Depression 100 8.9 87 8.7 83 -0.39 1.7 -0.228 0.041 -0.448    -0.008 73 8.6 70 -0.46 1.7 -0.262 0.031 -0.501     0.023 
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Appendix 2: Pre-operative (baseline) and post-operative (2- and 3-years) Health Related Quality of Life (HRQL) domain scores and change at 2- and 3-years in 
patients with immediate LDI breast reconstructions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complete data set for Figures 2A and B. Abbreviations: LDI, implant-assisted latissiumus dorsi breast reconstruction; HRQL, Health-Related Quality of Life; N, number; EORTC QLQ, 
European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaires; QoL, quality of life; FACT-B, Functional Assessment of Cancer Therapy-Breast; 
HADS, Hospital Anxiety and Depression Scale. S.D., Standard Deviation. P <0.01 (Bold) indicates a significant mean difference in scores from baseline with positive or negative (-) 
directions of effects. CI indicates 95% confidence intervals. Effect-sizes (ES) measured by Cohen’s d statistic defined as the difference between two means divided by the pooled 
standard deviation where <0.2 indicates a ‘trivial’ ES, 0.2-0.5 indicates a ‘small’ ES, 0.5-0.8 indicates a ‘medium’ ES and >0.8 indicates a ‘large’ ES
(24-27)
.  
HRQL Subscale Baseline      2 years          HRQL Change over 2 years      3 years HRQL Change over 3 years 
n Mean 
Score 
n Mean 
Score 
n Mean 
Change 
S.D. Effect- 
size 
p-value 95% CI n Mean 
Score 
n Mean 
Change 
S.D Effect- 
size 
p-value 95% CI 
EORTC QLQ-C30 and QLQ-BR23 
Global QoL 77 74.6 67 74.9 66 0.51 19.4 0.026 0.834 -0.220      0.272 50 76.8 49 2.72 24.0 0.114 0.430  -0.172      0.400 
Physical Function 77 94.5 67 91.1 66 -3.13 13.8 -0.228 0.069 -0.474      0.018 50 91.6 49 -2.59 14.6 -0.177 0.223 -0.463       0.109 
Role Function 77 89.6 67 88.8 66 -0.25 25.4 -0.010 0.936 -0.256      0.236 50 87.3 49 -3.40 31.4 -0.108 0.451  -0.394      0.178 
Emotional Function 77 66.8 67 79.0 66 11.87 23.2 0.511 <0.001 0.265        0.757 50 79.3 49 9.98 27.2 0.366 0.014   0.080       0.652 
Social Function 77 84.2 67 90.3 66 5.81 22.0 0.264 0.036 0.018        0.510 50 90.3 49 5.10 25.7 0.198 0.172  -0.088      0.484 
Pain 77 9.5 67 14.4 66 4.80 20.0 0.240 0.056 -0.006      0.486 50 13.3 49 4.08 23.5 0.174 0.229  -0.112      0.460 
Fatigue 77 21.4 67 20.6 66 -1.52 24.0 -0.063 0.610 -0.309      0.183 50 19.1 49 -2.04 27.8 -0.073 0.610  -0.359      0.213 
Breast Symptoms 74 13.1 67 10.6 64 -3.26 16.6 -0.196 0.123 -0.446      0.054 48 6.1 45 -8.52 15.3 -0.556 0.001   -0.854     -0.258 
Arm Symptoms 74 8.0 67 9.3 64 0.69 17.8 0.039 0.756 -0.211      0.289 48 10.6 45 1.23 19.1 0.065 0.667  -0.233      0.363 
Sexual Function 74 68.2 64 63.5 62 -5.38 27.6 -0.195 0.130 -0.449      0.059 48 57.6 45 -8.52 25.8 -0.330 0.032  -0.628     -0.032 
Body Image Scale 74 81.4 67 70.9 64 -10.03 29.8 -0.336 0.009  -0.586     -0.086 50 73.5 46 -11.05 30.5 -0.362 0.018  -0.658     -0.066 
FACT-B 
Physical WB 77 24.9 66 24.7 66 -0.18 4.5 -0.040 0.745 -0.286      0.206 50 25.2 49 0.45 4.6 0.097 0.499  -0.189      0.383 
Social WB 77 24.2 66 22.8 66 -1.56 4.5 -0.348 0.006  -0.593     -0.103 50 22.5 49 -2.23 4.3 -0.520 0.001  -0.806     -0.234 
Emotional WB 77 16.0 66 18.7 66 2.93 4.9 0.595 <0.001  0.349        0.841 50 19.3 49 2.95 4.5 0.659 <0.001  0.373        0.945 
Functional WB 77 20.7 67 22.4 67 2.09 6.4 0.327 0.009  0.083        0.571 50 21.7 49 0.73 7.2 0.101 0.482  -0.185      0.387 
Breast Cancer Subscale 74 26.3 66 27.0 63 0.37 7.3 0.051 0.690 -0.201      0.303 49 27.7 45 0.97 7.0 0.138 0.359  -0.160      0.436 
FACT-B Total 78 109.6 66 115.5 66 5.03 20.3 0.248 0.049 0.002        0.494 50 115.8 50 6.51 26.9 0.242 0.093  -0.041      0.525 
HADS 
Anxiety 77 10.6 66 11.5 65 0.88 3.0 0.292 0.022 0.044        0.540 50 12.0 49 1.16 2.6 0.441 0.003  0.155        0.727 
Depression 76 9.3 66 8.4 64 -0.84 1.7 -0.490 <0.001   -0.740    -0.240 50 8.5 48 -0.69 1.9 -0.363 0.015  -0.652     -0.074 
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